Tanvex BioPharma submits filgrastim biosimilar to Health Canada

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Tanvex BioPharma submits filgrastim biosimilar to Health Canada

Biosimilares/Novedades | Posted 01/02/2019 0 Post your comment

Taiwan-based biosimilars developer Tanvex BioPharma (Tanvex) announced on 16 January 2019 that it had submitted a biosimilar application to Health Canada for its proposed filgrastim biosimilar TX01.

TX01 is a proposed biosimilar to Amgen’s Neupogen (filgrastim), which had worldwide sales of US$1.4 billion in 2013 before the approval of the first filgrastim biosimilars. The patents on Neupogen expired in the US in December 2013 and in Europe in 2006 [1]. In Canada, according to IMS data, filgrastim product sales (including Neupogen and Grastofil) were over US$100 million for the 12 months ending 30 November 2018.

Filgrastim is a granulocyte colony-stimulating factor (G-CSF). Filgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment.

This is Tanvex’s second submission for its filgrastim biosimilar candidate. The company also had its application for TX01 accepted by the US Food and Drug Administration (FDA) back in November 2018 [2].

According to Dr Allen Chao, CEO of Tanvex BioPharma, this additional filing confirms the support of the company for the biosimilar market and its strategy ‘to explore additional opportunities that improve affordability and access to high quality biologics’.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Feb 1]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US
2. GaBI Online - Generics and Biosimilars Initiative. Tanvex BioPharma submits filgrastim biosimilar to FDA [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Feb 1]. Available from: www.gabionline.net/Biosimilars/News/Tanvex-BioPharma-submits-filgrastim-biosimilar-to-FDA

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Tanvex